Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals PLC has completed its $250 million share repurchase program, with the second and final tranche concluding on August 27, 2026. Under this final tranche, 6,062,420 ordinary shares were repurchased at an average price of £15.3733, costing £93,199,556.36. In total, since the program's launch on February 26, 2026, Hikma has bought back 13,138,823 shares for £186,264,205.19. Following the cancellation of these repurchased shares, the company will have 208,747,630 ordinary shares in issue.

Disclaimer*

UK 100

Latest directors dealings